December 15, 2021
Arcadia's new study, published on medRxiv, shows that current vaccines reduce the risk of long-COVID, even when administered up to 12 weeks after a COVID diagnosis.
December 15, 2021
Clinical trials and studies of real-world evidence have demonstrated repeatedly that the three COVID-19 vaccines* authorized for emergency use or approved for use by the Food and Drug Administration are safe and effective at preventing COVID-19 infection, hospitalization, and death (1). A recent observational study of self-reported symptoms goes further, concluding that vaccination may also reduce the likelihood and intensity of long-COVID (2), a proposal that has been raised anecdotally, as well (3). As part of a federated research study with the COVID-19 Patient Recovery Alliance, Arcadia.io performed a retrospective analysis of the medical history of 240,648 COVID-19-infected persons to identity factors influencing the development and progression of long-COVID. This analysis revealed that patients who received at least one dose of any of the three COVID vaccines prior to their diagnosis with COVID-19 were 7-10 times less likely to report two or more long-COVID symptoms† compared to unvaccinated patients. Furthermore, unvaccinated patients who received their first COVID-19 vaccination within four weeks of SARS-CoV-2 infection were 4-6 times less likely to report multiple long-COVID symptoms, and those who received their first dose 4-8 weeks after diagnosis were still 3 times less likely to report multiple long-COVID symptoms compared to those who remained unvaccinated. This relationship supports the hypothesis that COVID-19 vaccination is protective against long-COVID and that that effect persists even if vaccination occurs up to 12 weeks after COVID-19 diagnosis.
September 27, 2021
Arcadia congratulates its MSSP ACO partners for achieving over $202 million in savings, averaging $5.9M per ACO (53% more than peers).
June 21, 2021
Burlington, Mass. (June 21, 2021) – Arcadia (arcadia.io), the leading population health management and health intelligence platform, today announced that it has been cited by KLAS Research as one of today’s most well-rounded population health management (PHM) vendors,4 standing out
June 18, 2021
Widely-respected independent analyst firm KLAS Research just published their Population Health Vendor Overview 2021 report, recognizing Arcadia for our "customer experience, market energy, and breadth of PHM capabilities".3 "Their customers include some of the country’s largest healthcare organizations and some of the organizations most aggressively pursuing value-based care practices," reported KLAS.
June 16, 2021
Healthcare data platform Arcadia Analytics earned the highest ratings in the first-ever Cybersecurity Preparedness Evaluation from widely-respected healthcare research and insights firm KLAS Research. The evaluation was conducted independently by Censinet, the leading intelligent risk network for healthcare.
April 28, 2021
Gartner makes three recommendations for CIOs: 1) Reengineer your data services layer by investing in next-generation smart data technologies. Develop a pipeline of data tools and enablers across your digital architecture. 2) Move AI from the lab to value realization by focusing on the human elements of culture and frontline adoption. Democratize ownership by engaging end users early and continuously. 3) Break down and reconstruct your data governance processes and models. Drive improved enterprise data agility and collaboration by using adaptive data governance and DataOps approaches.
February 2, 2021
Arcadia enables economic success for large, innovative healthcare organizations; Arcadia Analytics has measured 134.6M patients and contains $275B in health costs. On average Arcadia ACO customers perform 2.5x better than peers
January 21, 2021
We congratulate Micky Tripathi, PhD, MPP on his new leadership role as the National Coordinator for Health Information Technology (ONC) at the Department of Health and Human Services. Micky was formerly the chief alliance officer at Arcadia.